Professor, Medicine, Tulane University School of Medicine
Hematology
Dr. Cindy A. Leissinger, MD
|
|
Give Review
Cindy Leissinger practices Hematology. She over the years received 1 awards: "Super Doctor". Doctor Cindy A. Leissinger, MD is a published doctor and has 56 publications published. The lastest was: 'Concurrence of anaphylaxis and acute heparin-induced thrombocytopenia in a patient with heparin-induced antibodies.' She accepts all Medicare patients.
Publications
- Desmopressin (DDAVP) in the management of patients with congenital bleeding Disorders.
- No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.
- Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors.
- Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII.
- The literature on inhibitors: Articles that influence my management of patients with Hemophilia A and high-titer inhibitors.
- Reduced production of IFN-? and LT-? is associated with successful prednisone therapy in patients with acquired Hemophilia A: A pilot study.
- Current management of acquired factor VIII inhibitors.
- Role of prothrombin complex concentrates in reversing warfarin antiCoagulation: a review of the literature.
- Inhibitor development in patients with Hemophilia: an overview.
- Diabetes treatments have differential effects on nontraditional cardiovascular risk factors.
- Prevention of bleeds in Hemophilia patients with inhibitors: emerging data and clinical direction.
- Effect of human immunodeficiency virus infection on hepatitis C virus infection in Hemophiliacs.
- Factor V Leiden is not responsible for stroke in patients with sickling Disorders and is uncommon in African Americans with sickle cell disease.
- Phenotypic expressions of CCR5-delta32/delta32 homozygosity.
- Continuous intraVenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B.
- Hepatitis G virus in clotting factor concentrates.
- Treatment of chronic haemophilic synovitis in humans with D-penicillamine.
- Unresolved issues in prophylaxis.
- High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand dis...
- Risk factors for infection with HBV and HCV in a largecohort of Hemophiliac males.
- A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.
- Application of current knowledge to the management of bleeding events during Immune tolerance induction.
- Factor IX pharmacokinetics: differences between plasma-derived and recombinant products and the clinical and economic implications: a meeting report.
- Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A.
- A consensus Statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
- Anti-inhibitor coagulant complex prophylaxis in Hemophilia with inhibitors.
- Rituximab therapy modulates IFN-gamma and IL-4 gene expression in a patient with acquired haemophilia A.
- Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.
- Dose of prophylactic Platelet transfusions and prevention of hemorrhage.
- Immune tolerance induction for the eradication of inhibitors in patients with Hemophilia A.
- Emergency department care for patients with Hemophilia and von Willebrand disease.
- Prophylaxis versus episodic treatment to prevent joint disease in boys with severe Hemophilia.
- New approaches to using FEIBA in the treatment of inhibitor patients.
- Evidence of HIV exposure and transient seroreactivity in archived HIV-negative severe Hemophiliac sera.
- End-stage liver disease in persons with Hemophilia and transfusion-associated infections.
- Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe Hemophilia B.
- Concurrence of anaphylaxis and Acute heparin-induced thrombocytopenia in a patient with heparin-induced antibodies.
- Activity of granzyme A, a serine protease in the killing granules of cytotoxic T lymphocytes, is reduced in cells from HIV-infected Hemophiliacs.
- Absence of seroconversion of HIV-1 antibody in seroreactive individuals.
- The nonspecific nature of Platelet-associated IgG.
- Evaluation by quantitative acid elution and radioimmunoassay of multiple classes of immunoglobulins and serum albumin associated with Platelets in idiopathic thrombocy...
- Severe thrombocytopenia associated with cocaine use.
- Role of splenectomy in the management of hemophilic patients with human immunodeficiency virus-associated immunopathic Thrombocytopenic purpura.
- Unbound immunoglobulins are a major source of error in the quantitation of Platelet surface-bound immunoglobulin levels.
- Platelet kinetics in Immune thrombocytopenic purpura and human immunodeficiency virus thrombocytopenia.
- Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors.
- Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and ...
- Prophylaxis in haemophilia patients with inhibitors.
- Inhibitor treatment in haemophilias A and B: summary Statement for the 2006 international consensus conference.
- Inhibitor development and successful Immune tolerance in an HIV-infected patient with haemophilia A and after Immune reconstitution with HAART.
- Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population.
- Haemobilia after transjugular liver biopsy in a patient with severe haemophilia.
- Maintenance of treatment logs by haemophilia patients.
- The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.
- Prospective, multicenter study of postoperative Deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery.
Schools
Tulane University of Louisiana
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Drug Facts
| NPI NUMBER | 1700839933 | |
| NPPES Provider LastName | LEISSINGER | |
| NPPES Provider FirstName | CINDY | |
| NPPES Provider ZIPCode | 701122600 | |
| NPPES Provider State | LA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 132.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 34.0 | |
| Percent Opioid Claims | 25.76 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1700839933 |
| Last Name Of The Provider | LEISSINGER |
| First Name Of The Provider | CINDY |
| View All |
Similar Doctors
|
|
Dr. Milton W. Seiler Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. John T. Cole, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marc J. Kahn, MD |
|
Dr. Charles V. Wendling Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Suma P. Satti, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bridgette M. Collins Burow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gary E. Lipscomb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ramesh K. Bhagat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura E. Miller, MD |
|
|
Dr. John R. Krause, MD |